Is Beam Therapeutics Inc. (BEAM) a Buy, Sell, or Hold?
Beam Therapeutics Inc.
NASDAQ:BEAM
$30.89 USD
-$0.11 (-0.35%)
- Volume
- 2.01M
- Average Volume
- 2.29M
- Market Capitalization
- $3.18B
- P/E Ratio
- -48.27
- Dividend Yield
- 0.00%
- Price Target
- $41.00
- Year High
- $38.26
- Year Low
- $15.60
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $16.99
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | John Evans |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BEAM |
| CUSIP | 07373V105 |
| CIK | 0001745999 |
| Web | https://www.beamtx.com |
| Phone | 857 327 8775 |
| Currency | USD |
| Employees | 522 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.22 |
| Payout Ratio | 0.00 |
| Current Ratio | 16.99 |
| Quick Ratio | 16.99 |
| Cash Ratio | 3.87 |
Sales & Book Value
| Annual Sales | $139.74M |
| Price / Sales | 19.38 |
| Cash Flow | -3.72 |
| Price / Cash Flow | -8.28 |
| Price / Book | 2.74 |
Price Target and Rating
| Average Stock Price Forecast | $41.00 |
| High Stock Price Forecast | $80.00 |
| Low Stock Price Forecast | $26.00 |
| Forecast Upside/Downside | -24.66% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 27 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.81 |
| Trailing P/E Ratio | -48.27 |
| PEG Ratio | -0.33 |
| P/E Growth | -0.33 |
| Net Income | $-79.99M |
| Net Margin | -39.66% |
| Pretax Margin | -39.66% |
| Return on Equity | -5.89% |
| Return on Assets | -4.39% |
Financials Score
| AltmanZ Score | 5.40 |
| Piotroski Score | 3.00 |
| Working Capital | 1.19B |
| Total Assets | 1.48B |
| Ebit | -54.4M |
| Market Cap | 3.21B |
| Total Liabilities | 316.36M |
Poll Results
About Beam Therapeutics Inc. (NASDAQ:BEAM) Stock
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these fla ... gship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
2026-07-09 10:22:58
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers precise, versatile gene correction using LNP delivery, but remains preclinical with IND/CTA filings for PM647 expected mid-2026 and initial clinical data in 2027. PRME lags competitors like Beam, Sanofi, and Arrowhead in the AATD development race, facing significant funding needs and clinical risks.
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case
2026-07-08 13:29:41
Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dispute with Beam Therapeutics Inc. (NASDAQ:BEAM).
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
2026-07-08 05:45:00
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
2026-06-29 10:35:25
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips.
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
2026-06-19 11:36:04
Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-targeted gene-editing program into clinical testing.
2026-06-18 07:00:00
BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU BEAM-304 Program Designed as Platform-based Approach Reflecting Emerging FDA Guidance for Accelerated Development of Genome Editing Therapies New Preclinical Data for BEAM-304 to be Presented at FASEB Genome Engineering: Research and Applications Conference CAMBRIDGE, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BEAM-304 for the treatment of phenylketonuria (PKU).
2026-06-17 12:30:08
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
2026-06-16 09:51:26
BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runway into mid-2029 boost investor confidence.
Frequently Asked Questions
-
What is the current Beam Therapeutics Inc. (BEAM) stock price?
-
Beam Therapeutics Inc.(NASDAQ:BEAM) stock price is $30.89 in the last trading session. During the trading session, BEAM stock reached the peak price of $38.26 while $15.6 was the lowest point it dropped to. The percentage change in BEAM stock occurred in the recent session was --0.35% while the dollar amount for the price change in BEAM stock was -$-0.11.
-
BEAM's industry and sector of operation?
-
The NASDAQ listed BEAM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BEAM?
-
Amy Simon | Chief Medical Officer
J. Keith Joung | Co-Founder
Gopi Shanker | Chief Scientific Officer
Manmohan Singh | Chief Technology Officer
Bethany J. Cavanagh | Senior VP of Finance, Treasurer & Principal Accounting Officer -
How many employees does BEAM have?
-
Number of BEAM employees currently stands at 522. BEAM operates from 238 Main Street, Cambridge, MA 02142, US.
-
Link for BEAM official website?
-
Official Website of BEAM is: https://www.beamtx.com
-
How do I contact BEAM?
-
BEAM could be contacted at phone #857 327 8775 and can also be accessed through its website. BEAM operates from 238 Main Street, Cambridge, MA 02142, US.
-
How many shares of BEAM are traded daily?
-
The average number of BEAM shares traded daily for last 3 months was 2.29M.
-
What is the market cap of BEAM currently?
-
The market value of BEAM currently stands at $3.18B with its latest stock price at $30.89